Valuation: Curis, Inc.

Market Cap 1.59M 1.42M 1.31M 1.19M 2.22M 151M 2.26M 15.79M 6.24M 78.9M 5.95M 5.82M 250M P/E 2026 *
-0.02x
P/E 2027 * -0.05x
Enterprise Value 1.59M 1.42M 1.31M 1.19M 2.22M 151M 2.26M 15.79M 6.24M 78.9M 5.95M 5.82M 250M EV / Sales 2026 *
-
EV / Sales 2027 * 0.17x
Free-Float
96.19%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Curis, Inc.

1 day-4.74%
1 week-3.07%
Current month-55.91%
1 month-55.51%
3 months-92.11%
6 months-96.82%
Current year-98.13%
1 week 0.36
Extreme 0.3625
0.42
1 month 0.32
Extreme 0.325
0.86
Current year 0.32
Extreme 0.325
24.2
1 year 0.32
Extreme 0.325
33
3 years 0.32
Extreme 0.325
349.8
5 years 0.32
Extreme 0.325
2,832
10 years 0.32
Extreme 0.325
7,440
Manager TitleAgeSince
Chief Executive Officer 59 23/09/2018
Director of Finance/CFO 54 04/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 31/10/2003
Chairman 84 15/05/2017
Director/Board Member 71 02/06/2010
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26 Free

Chief Executive Officer

110,090 0.2824%
07/07/26 Free

Director

6,800 0.0174%
07/07/26 Free

Chairman

6,800 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-6.16%-3.07%-98.81%-99.54% 1.59M
+0.88%+1.18%+40.64%+74.91% 64.69B
-0.26%+6.91%+9.79%+77.36% 54.78B
+0.47%+3.52%+9.71%+100.95% 53.49B
-1.16%+3.28%+26.29%+48.90% 45.98B
-1.51%+0.69%+18.16%+124.74% 42.94B
-1.14%+1.47%+218.72%+828.30% 40.08B
-2.26%-2.06%+15.38%+45.14% 33.52B
+0.22%-4.77%+26.59%+0.55% 23.97B
+12.10%+16.60%+58.50%+46.15% 23.67B
Average +0.27%+1.49%+32.50%+124.75% 38.31B
Weighted average by Cap. +0.33%+2.59%+44.31%+151.14%

Financials

2026 *2027 *
Net sales - 9.25M 8.27M 7.65M 6.93M 12.97M 880M 13.18M 92.09M 36.43M 460M 34.72M 33.98M 1.46B
Net income -52.02M -46.51M -43.03M -38.96M -72.93M -4.95B -74.12M -518M -205M -2.59B -195M -191M -8.2B -45.23M -40.45M -37.42M -33.88M -63.41M -4.3B -64.45M -450M -178M -2.25B -170M -166M -7.13B
Net Debt - -
Projected Income Statement - Annual - Curis, Inc.
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
26/10/26 US$0.3625 -6.16% 77,485
23/10/26 US$0.3863 -4.59% 66,864
22/10/26 US$0.4049 +3.29% 158,201
21/10/26 US$0.3920 -1.90% 96,019
20/10/26 US$0.3996 +4.72% 217,997
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Curis, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.3863USD
Average target price
42.67USD
Spread / Average Target
+10,944.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Curis, Inc.
  1. Stock Market
  2. Stocks
  3. CRIS Stock